SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Quint Jennifer K.)
 

Sökning: WFRF:(Quint Jennifer K.) > SABINA :

  • Janson, ChristerUppsala universitet,Lung- allergi- och sömnforskning (författare)

SABINA : An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • 2020-01-24
  • Springer Science and Business Media LLC,2020
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-425647
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-425647URI
  • https://doi.org/10.1007/s12325-020-01233-0DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • IntroductionGlobally, individuals with asthma tend to overrely on short-acting β2-agonists (SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying inflammation. Such relief-seeking behavior has been reinforced by long-standing treatment guidelines, which until recently recommended SABA-only use for immediate symptom relief. We aimed to describe the current burden of SABA use among European individuals with asthma within the SABA use IN Asthma (SABINA) program.MethodsPrescription and/or dispensing data during 2006–2017 from electronic medical records and/or national patient registries in the United Kingdom (UK), Germany, Italy, Spain, and Sweden were analyzed. Individuals aged at least 12 years old with a current asthma diagnosis and no other chronic respiratory conditions were included. Asthma treatment step and severity were based on treatment guidelines in use in each individual country. The proportion of individuals prescribed SABA was measured during a 12-month period. SABA overuse was defined as at least three SABA canisters per year.ResultsMore than one million individuals with asthma were included across five European countries. Overall, the majority of individuals were over 45 years of age, except in Sweden (mean age 27.6 years) where individuals aged over 45 years were excluded to avoid a potential chronic obstructive pulmonary disease co-diagnosis. The study population was predominantly female (55–64%), except in the UK (46%). The prevalence of SABA overuse was 9% in Italy, 16% in Germany, 29% in Spain, 30% in Sweden, and 38% in the UK. In the UK, SABA overuse was greater in individuals with moderate-to-severe asthma versus individuals with mild asthma (58% versus 27%, respectively), while SABA overuse was similar in individuals with both mild (9–32%) and moderate-to-severe (8–31%) asthma in the other European countries.ConclusionsThe findings of this study from the SABINA program show that SABA overuse (at least three canisters per year) is common across Europe, despite the different healthcare and reimbursement policies of each country.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Menzies-Gow, AndrewRoyal Brompton Hosp, Lung Div, London, England (författare)
  • Nan, CassandraAstraZeneca, Biopharmaceut Med, Gothenburg, Sweden (författare)
  • Nuevo, JavierAstraZeneca, Biopharmaceut Med, Serrano Galvache 56, Madrid 28033, Spain (författare)
  • Papi, AlbertoUniv Ferrara, Dept Med Sci, Ferrara, Italy (författare)
  • Quint, Jennifer K.Imperial Coll London, Natl Heart & Lung Inst, Resp Epidemiol Occupat Med & Publ Hlth, London, England (författare)
  • Quirce, SantiagoLa Paz Univ Hosp, Dept Allergy, Madrid, Spain; CIBER Resp Dis CIBERES, Madrid, Spain (författare)
  • Vogelmeier, Claus F.Philipps Univ Marburg, Univ Med Ctr Giessen & Marburg, Dept Med Pulm & Crit Care Med, Marburg, Germany; German Ctr Lung Res DZL, Marburg, Germany (författare)
  • Uppsala universitetLung- allergi- och sömnforskning (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Advances in Therapy: Springer Science and Business Media LLC37:3, s. 1124-11350741-238X1865-8652

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy